EPL Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Record revenue, raised guidance: Revenue grew 25.3% (20% ex-pricing pass-through), prompting management to raise the growth outlook to high teens for the coming quarters.
• Cost recovery muscle proved again: The entire raw material, freight, and currency cost impact was recovered through pricing in the quarter, demonstrating the business model's ability to navigate volatile commodity cycles.
• Europe is the growth bet with margin work to do: Europe delivered 20%+ revenue growth and is seen as the future growth engine, but operational inefficiencies are now getting disproportionate focus to progressively recover margins toward the mid-teens target.
• PAT optics mask underlying strength: PAT declined 1.4% solely due to a low base-year effective tax rate; PBT grew 10% and full-year PAT is on track for double-digit growth.
• What to watch next quarter: The pace of Europe's margin recovery, the closing of the Indovida merger, and whether Oral Care's exceptional 24% growth normalizes.

Top-Line Performance & Regional Mix

• Broad-based growth: Every region delivered double-digit growth: EAP 34.3%, Americas 29.4%, Europe 20.2%, AMESA 17%.
• Portfolio shift underway: Personal Care & Beyond expanded to 54% of the portfolio, while Beauty & Cosmetics exceeded 20% growth and Oral Care crossed 20%.
• Oral Care surge: 24% growth this quarter, described as exceptional and not repeatable every quarter, driven by strong service and customer engagement during the crisis that won wallet share across many markets.
• Americas margin nuance: Revenue growth includes pricing impact, so underlying EBITDA margin is higher than reported; sequential March-to-June margins are not comparable due to investments in a divisionalized sales team and outsourcing of high-capability items.
• Thailand ramp-up: Operations are beginning to ramp up, contributing to the confidence behind the raised guidance.

Bakshi: "We've never had a quarter like this. And we've maintained underlying margins in line with our guidance."

Cost Recovery & Cyclicality-Proofing

• Two crisis principles met: Management committed to uninterrupted customer service and full cost recovery through pricing; both were achieved fully in Q1.
• Recovery mechanics: Customer contracts operate on a blended cost basis; pricing comes with some lag for a few customers, and old inventory consumption cost impact netted out against that lagged pricing.
• Built to handle cycles: Management states the business has built the muscle to recover price through strong tracking and review mechanisms around cost inflation and recovery, a lesson learned from past crises.
• High inflation to persist: The company expects to operate in a high inflationary environment for some time, making the demonstrated pricing discipline a recurring necessity.

Goyal: "One of our key focus areas is to make this business cyclicality proof because the commodity cycles will come and go. And that's exactly what you see demonstrated in our numbers in the quarter."

Europe: Growth Engine with Margin Drag

• Strategic bet: Europe is described as the biggest and most widespread B&C market, and the company has invested in it as the future of growth, including capacity expansion, new production capabilities, and front-end people.
• Identified drag: Operational challenges have been identified fully and are now getting disproportionate focus; specific cost programs are underway to address identified inefficiencies.
• Margin recovery path: As operational efficiency improves, margins are expected to progressively recover to the target range of mid-teens in coming quarters, with growth investments normalizing as scale leverage kicks in and specific cost programs addressing identified inefficiencies.
• Manufacturing footprint: The current position of manufacturing in Poland and Germany will stay in the near future; some capabilities have been centralized in Poland for both customer service and printing to drive efficiency and superior service.

Bakshi: "Europe is the biggest and a widespread B&C market. We have invested in Europe being the future of growth."

Indovida Merger & Capital Allocation

• CCI approval secured: The Competition Commission of India approved the merger during the quarter; the transaction continues to progress well toward the planned timeline.
• Strategic fit: The merger ticks all three boxes of management's vision to become a leader from emerging markets in consumer packaging: new capabilities, new markets, and building growth and margin.
• Indovida's standalone quarter: Indovida declared Q1 results with 11% volume growth, 25% revenue growth, 62% EBITDA growth, margin at 27%, and EBITDA of almost INR383 crores.
• EPS accretion promised: Management describes the merger as "very, very EPS accretive," with Indovida's PAT in line with EPL's PAT.
• M&A appetite remains: The company is actively scouting for acquisition opportunities that allow a move into new capabilities (new formats) or new markets, and must help build both growth and margin.
• Working capital build: Net working capital increased roughly ₹180 crores in the quarter, largely driven by inventory: pricing of inventory itself rose with raw material costs, and safety stock was built to ensure supply security and avoid disruptions. Receivables days and aging remain well under control.

Margins & Profitability

• EBITDA milestone: 15.2% EBITDA growth marks the 15th consecutive quarter of double-digit EBITDA growth, achieved by passing on the entire cost increase through judicious pricing across all regions and customers, plus a frugal mindset and relentless cost discipline.
• PAT divergence explained: Q1 PAT declined 1.4% while PBT increased 10% because the company is lapping a very low base-year effective tax rate; this will correct on a full-year basis, with the full-year ETR expected to land between 20% and 22%.
• EBIT impact from CapEx: A significant increase in CapEx, driven by investing ahead of the curve, is reflecting in EBIT numbers.
• Steady-state leverage: On a steady-state basis, EBITDA will grow faster than revenue growth.
• Margin guidance held: Management is holding on to guidance of 20% underlying EBITDA margin and expects to sustain it going forward.

Bakshi: "Our PAT delivery is fully in line with our plans to deliver a double-digit growth for the year. This quarter numbers are seeming low because of the effective tax rate and phasing issues."

Guidance & Commitments

Key Metrics